

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/229585129>

2 3 Synthesis and evaluation of 2,4,6-trisubstituted pyrimidine derivatives as novel antileishmanial agents

ARTICLE *in* MEDICINAL CHEMISTRY RESEARCH · JULY 2012

Impact Factor: 1.4 · DOI: 10.1007/s00044-012-0167-y

CITATIONS

4

READS

77

5 AUTHORS, INCLUDING:



[Neha Kawathekar](#)

SGSITS.INDORE

8 PUBLICATIONS 44 CITATIONS

SEE PROFILE



[Priyanka Kamaria](#)

Shri Govindram Seksaria Institute of Techn...

5 PUBLICATIONS 17 CITATIONS

SEE PROFILE

Synthesis and evaluation of 2,4,6-trisubstituted pyrimidine derivatives as novel antileishmanial agents

S. K. Patle, N. Kawathekar, M. Zaveri & P. Kamaria

Medicinal Chemistry Research

ISSN 1054-2523

Med Chem Res

DOI 10.1007/s00044-012-0167-y



Your article is protected by copyright and all rights are held exclusively by Springer Science+Business Media, LLC. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your work, please use the accepted author's version for posting to your own website or your institution's repository. You may further deposit the accepted author's version on a funder's repository at a funder's request, provided it is not made publicly available until 12 months after publication.

Synthesis and evaluation of 2,4,6-trisubstituted pyrimidine derivatives as novel antileishmanial agents

S. K. Patle · N. Kawathekar · M. Zaveri ·
P. Kamaria

Received: 9 September 2011 / Accepted: 28 June 2012
© Springer Science+Business Media, LLC 2012

Abstract A series of new 2,4,6-trisubstituted pyrimidine derivatives **8(a–j)** were synthesized by reacting substituted chalcones containing imidazole **6(a–d)** and benzimidazole **7(a–f)** with guanidine hydrochloride in the presence of strong base. Substituted chalcones were synthesized by reacting 4-(1H-imidazol-1-yl)benzaldehyde or 4-(1H-benzimidazol-1-yl)benzaldehyde with different substituted acetophenones in the presence of 40 % NaOH in methanol. The synthesized compounds were confirmed by IR, ¹HNMR, and mass spectral data and screened for antileishmanial activity. Antileishmanial activity was performed against *Leishmania donovani* parasite, and percentage lysis inhibition were calculated by meglumine antimoniate taking a positive control and chloroform (0.1 % CHCl₃) treatment served as control. Among all the compounds, **8h** and **8j** exhibited 50–57 % inhibition against promastigotes, thus providing new structural lead for antileishmanials.

Keywords Synthesis · Chalcones · Pyrimidines · Antileishmanial activity

Introduction

Leishmaniasis is a parasitic disease caused by 17 species of the protozoan parasite *Leishmania* (Chandra *et al.*, 2005) and transmitted by the bite of a sand-fly genus *Phlebotomus*. Three different forms of the diseases: visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous

leishmaniasis are present in the world (Bouhlef *et al.*, 2010). This disease is mostly endemic in 88 countries in the world, and visceral form of leishmaniasis is the most severe type among all types of leishmaniasis, known as kala-azar, which is caused by *Leishmania donovani* and is nearly always fatal, if untreated (Sunduru *et al.*, 2009). More than 12 million people were infected by this disease around the world (Bhandari *et al.*, 2010). Five lakh new cases of visceral leishmaniasis or kala-azar were found every year (Perez-Victoria *et al.*, 2006). Currently available drugs are ineffective due to emergence of resistance among parasites; also, chemotherapy of leishmaniasis is quite difficult due to significant toxicity, variable efficacy, lack of oral bioavailability, and high cost of the therapeutic agents. So novel antileishmanial agents are urgently needed (Srinivas *et al.*, 2009).

Mostly the nitrogen heterocycles such as quinolines, acridines, phenothiazines, pyrimidines, purines, bis-benzamides, pyrazolo[3,4b]pyridine, benzothiazoles, and imidazolidine were reported as antileishmanial agents (Agarwal *et al.*, 2009).

Most of the clinically used DHFR inhibitor shows less selectivity for leishmanial enzymes because the gene for pteridine reductase (PTR1) is amplified in some leishmanial mutants. Antifolate drugs simultaneously target both DHFR and PTR1 to be successful antileishmanials because PTR1 can reduce pterins and folates, and therefore, act as a bypass for DHFR inhibition. A number of compounds having pyrimidine moiety is reported to be potent inhibitor of PTR1 in *Leishmania* (Sunduru *et al.*, 2006).

Based on the above observations, we have synthesized hybrid derivatives of pyrimidine containing imidazole or benzimidazole. The synthesized compounds act as an

S. K. Patle · N. Kawathekar (✉) · M. Zaveri · P. Kamaria
Department of Pharmacy, Shri G.S. Institute of Technology
& Science (An Autonomous Institution), 23 Park Road,
Indore 452003, MP, India
e-mail: neha_kawathekar@yahoo.co.in

Scheme 1 Synthesis of 2,4,6-trisubstituted pyrimidine derivatives. *Reagent and conditions:* (I) $K_2CO_3/C_{16}H_{33}(CH_3)_3N^+Br^-$, 100 °C, stirrer, 28 h; (II) MeOH/NaOH/25 °C, stirrer, 50–60 min; (IIIa & IIIb) EtOH/NaOH/90 °C, reflux, 16 h










Table 1 General structures of synthesized compounds and anti-leishmanial activity of with respect to control



| Compound code | Molecular formula | R ₁ | R | Dose (µg/ml) | Biological activity* |
|---------------|--|----------------|--------------------|--------------|----------------------|
| 8a | C ₁₉ H ₁₅ N ₅ | | H | 10 | 32.81 |
| 8b | C ₁₉ H ₁₄ ClN ₅ | | 4-Cl | 10 | 46.14 |
| 8c | C ₁₉ H ₁₄ BrN ₅ | | 4-Br | 10 | 24.32 |
| 8d | C ₂₀ H ₁₇ N ₅ O | | 4-OCH ₃ | 10 | 18.14 |
| 8e | C ₂₃ H ₁₇ N ₅ | | H | 10 | 41.86 |

Table 1 continued

| Compound code | Molecular formula | R ₁ | R | Dose (μg/ml) | Biological activity* |
|---------------|--|---|--------------------|--------------|----------------------|
| 8f | C ₂₃ H ₁₆ FN ₅ |  | 4-F | 10 | 29.64 |
| 8g | C ₂₃ H ₁₆ ClN ₅ |  | 4-Cl | 10 | 32.67 |
| 8h | C ₂₃ H ₁₅ Cl ₂ N ₅ |  | 2,4-Cl | 10 | 56.42 |
| 8i | C ₂₃ H ₁₆ BrN ₅ |  | 4-Br | 10 | 32.49 |
| 8j | C ₂₄ H ₁₉ N ₅ O |  | 4-OCH ₃ | 10 | 51.18 |

* Percentage lysis with respect to control

inhibitor of PTR1 as well as an inhibitor of DHFR and thus act as potential antileishmanial agents.

Scheme 1I, III); (Trivedi *et al.*, 2008; Rashinkar *et al.*, 2009).

Chemistry

N-arylation of imidazole or benzimidazole was carried out with para-fluorobenzaldehyde using hexadecyltrimethylammonium bromide as a catalyst to yield compounds 4-(1H-imidazol-1-yl) benzaldehyde (**4**) or 4-(1H-benzo[d]imidazol-1-yl)benzaldehyde (**5**). Compounds **4** and **5** were reacted with substituted acetophenones in the presence of base (40 % NaOH in methanol) to afford substituted chalcones by Claisen Schmidt condensation (**6a–d**, Scheme 1I, IIa and **7a–f**, 1I, IIb), (Hussain *et al.*, 2009).

The formation of pyrimidine ring from chalcone proceeds via Michael reaction followed by cyclization (Micky *et al.*, 2006). Different substituted chalcones were cyclized by guanidine hydrochloride in the presence of base using ethanol as a solvent to yield pyrimidine derivative (**8a–j**,

Result and discussion

Chemistry

Absorbance band at 3,323–3,487 cm^{−1} which indicates the presence of aromatic primary amino group (−NH₂). IR data confirms the presence of specific functional groups present in all the synthesized compounds. Absorbance at 813–740 cm^{−1}; 542–594 cm^{−1}; 1,053–1,230 cm^{−1}, and 1,232–1,255 cm^{−1} indicates the presence of C–Cl, C–Br, C–F, and C–OCH₃ substitution groups in synthesized compound, respectively.

The presence of 7.26–7.15 δ ppm (1H, s, pyrimidine) indicates the formation of pyrimidine ring at synthesized compound. The presence of 5.89–6.45 δ ppm (2H, s, −NH₂) indicates the amino group (−NH₂) at synthesized

compound. 3.84 δ ppm values indicate the presence of methoxy group in synthesized compound.

Biological activity

Biological evaluation was performed against *L. donovani* strain, and percentage lysis inhibition was calculated by maglumine antimoniate as positive control (Table 1). 4-Cl substitution on aromatic phenyl ring increases the biological activity and 2,4 dichloro substitution on aromatic phenyl ring further increases the biological activity. A 4-OCH₃ substituted benzimidazole derivative was found to be more potent than 4-OCH₃ substituted imidazole derivatives. **8h** and **8j** were the most potent compounds of the series and shows more than 50 % inhibition against promastigotes.

Conclusion

2,4,6-Trisubstituted pyrimidine derivatives were synthesized and confirmed by IR, ¹H NMR and Mass spectral data and screened for antileishmanial activity. Compounds **8h** and **8j** exhibited 56.42 and 51.18 % inhibition against promastigotes, respectively, thus providing lead structure for antileishmanials.

Experimental

Melting points of synthesized compounds were identified by open capillary method and were uncorrected. Infrared (IR) spectra were recorded using Shimadzu FTIR (SGSITS Indore). Nuclear magnetic resonance (¹H NMR) spectra were recorded on Bruker Avance II, 400 MHz Spectrophotometer (Panjab University) using DMSO as a solvent and TMS as internal standard (Chemical shift in δ ppm). Spin multiplates are given as *s* (singlet), *d* (doublet), *t* (triplet), and *m* (multiplet). Mass spectra were recorded on GCMS solution\system\tune1\Auto Tuning-EI (IICT Hyderabad). Biological activity of synthesized compounds was performed from Pharmbio Research Center Pvt. Ltd., Indore.

Synthesis of 4-(1H-imidazol-1-yl)benzaldehyde (**4**; Scheme 1I, Ia)

A mixture of imidazole **2** (6.8 g, 100 mmol), anhydrous potassium carbonate (13.80 g, 100 mmol), 4-fluorobenzaldehyde **1** (12.40 g, 100 mmol), hexadecyltrimethylammonium bromide (20 mg), and DMF (50 ml) was stirred for a period of 28 h at 100 °C, and after cooling to room temperature, was poured on to

crushed ice (200 ml). Pale yellow crystals obtained were filtered, dried, and recrystallized from methanol (Hussain *et al.*, 2009).

Synthesis of 4-(1H-benzo[d]imidazol-1-yl)benzaldehyde (**5**; Scheme 1I, Ib)

A mixture of benzimidazole **3** (11.8 g, 100 mmol), anhydrous potassium carbonate (13.80 g, 100 mmol), 4-fluorobenzaldehyde **1** (12.40 g, 100 mmol), hexadecyltrimethyl ammonium bromide (20 mg), and DMF (50 ml) was stirred for a period of 28 h at 100 °C, and after cooling to room temperature, was poured on to crushed ice (200 ml). Pale yellow crystals obtained were filtered, dried, and recrystallized from methanol.

Synthesis of 3-(4-(1H-imidazol-1-yl)phenyl)-1-phenylprop-2-en-1-one (**6a-d**; Scheme 1I, IIa)

A methanolic sodium hydroxide solution (40 %, 10 mmol) was added dropwise to a mixture of 4-(1H-imidazol-1-yl)benzaldehyde (10 mmol), acetophenone (10 mmol), and methanol over a period of 50–60 min with continuous stirring till completion of reaction (as indicated by TLC). Precipitates obtained were filtered and washed with cold methanol–water mixture (1:10). Finally, the product was recrystallized from methanol (Hussain *et al.*, 2009).

Synthesis of 3-(4-(1H-benzo[d]imidazol-1-yl)phenyl)-1-phenylprop-2-en-1-one (**7a-f**; Scheme 1I, IIb)

A methanolic sodium hydroxide solution (40 %, 10 mmol) was added dropwise to a mixture of 4-(1H-benzo[d]imidazol-1-yl)benzaldehyde (10 mmol), acetophenone (10 mmol), and methanol over a period of 50–60 min with continuous stirring till completion of reaction (as indicated by TLC). Precipitates obtained were filtered and washed with cold methanol–water mixture (1:10). Finally, the product was recrystallized from methanol (Hussain *et al.*, 2009).

Synthesis of 4-(4-(1H-imidazol-1-yl)phenyl)-6-phenylpyridine-2-amine (**8a-d**; Scheme 1I, IIIa)

Guanidine hydrochloride (3 mmol) was dissolved in 12 ml 5 % ethanolic solution of NaOH. Synthesized chalcones (**6a-d**) was added to it and refluxed for 16 h. Solution was cooled at room temperature and poured into the crushed ice. Precipitate was filtered and washed with cold water. The crude product was dried and recrystallised from ethanol than methanol (Rashinkar *et al.*, 2009).

4-(4-(1*H*-imidazol-1-yl)phenyl)-
6-(4-chlorophenyl)pyrimidin-2-amine (**8a**)

% Yield: 42. MP (°C): 234–236. IR (KBr, cm⁻¹): 3109, 3454, 1520, 1051, 813. ¹H NMR (DMSO, 400 MHz) δ : 8.33(2H, d, Ar-H), 8.20(3H, t, Ar-H), 8.05(1H, s, imidazole), 7.71–7.64(3H, m, Ar-H), 7.51(2H, d, imidazole), 7.15(1H, s, pyrimidine), 6.45(2H, s, -NH₂). Mass (*m/z*): 347.

4-(4-(1*H*-imidazol-1-yl)phenyl)-6-phenylpyrimidin-2-amine (**8b**)

% Yield: 40. MP (°C): 136–138. IR (KBr, cm⁻¹): 3128, 3371, 1543, 1053. ¹H NMR (DMSO, 400 MHz) δ : 8.36(2H, d, Ar-H), 8.28(3H, t, Ar-H), 8.23(1H, s, imidazole), 7.72(2H, d, imidazole), 7.66–7.61(4H, m, Ar-H), 7.26(1H, s, pyrimidine), 5.89(2H, s, -NH₂). Mass (*m/z*): 313.

4-(4-(1*H*-imidazol-1-yl)phenyl)-
6-(4-bromophenyl)pyrimidin-2-amine (**8c**)

% Yield: 46. MP (°C): 230–233. IR (KBr, cm⁻¹): 3113, 3458, 1519, 1051, 586. ¹H NMR (DMSO, 400 MHz) δ : 8.31(2H, d, Ar-H), 8.10(3H, t, Ar-H), 7.94(1H, s, imidazole), 7.67–7.59(5H, m, Ar-H), 7.16(1H, s, pyrimidine), 6.31(2H, s, -NH₂). Mass (*m/z*): 391.

4-(4-(1*H*-imidazol-1-yl)phenyl)-
6-(4-methoxyphenyl)pyrimidin-2-amine (**8d**)

% Yield: 40. MP (°C): 205–208. IR (KBr, cm⁻¹): 3107, 3454, 1514, 1051, 1255. ¹H NMR (DMSO, 400 MHz) δ : 8.33(3H, t, Ar-H), 8.18(2H, d, imidazole), 7.76(3H, d, Ar-H), 7.63(1H, s, imidazole), 7.14(1H, s, pyrimidine), 7.02(2H, d, Ar-H), 6.51(2H, s, -NH₂), 3.85(3H, s, -OCH₃). Mass (*m/z*): 343.

Synthesis of 4-(4-(1*H*-benzo[d]imidazol-1-yl)phenyl)-
6-phenylpyridine-2-amine (**8e–j**; Scheme 11, IIb)

Guanidine hydrochloride (3 mmol) was dissolved in 12 ml 5% ethanolic solution of NaOH. Synthesized chalcones (**7a–f**) were added to it and refluxed for 16 h. Solution was cooled at room temperature and poured into the crushed ice. Precipitate was filtered and washed with cold water. The crude product was dried and recrystallized from ethanol then methanol (Rashinkar *et al.*, 2009).

4-(4-(1*H*-benzo[d]imidazol-1-yl)phenyl)-
6-(4-fluorophenyl)pyrimidin-2-amine (**8e**)

% Yield: 42. MP (°C): 182–184. IR (KBr, cm⁻¹): 3086, 3487, 1510, 1014, 1230. ¹H NMR (DMSO, 400 MHz) δ :

8.38(2H, d, Ar-H), 8.33(1H, s, imidazole), 8.28(2H, d, Ar-H), 8.20–8.16(2H, m, Ar-H), 7.84(1H, d, imidazole), 7.75(3H, t, Ar-H), 7.38–7.35(2H, m, Ar-H), 7.26(1H, s, pyrimidine), 6.04(2H, s, -NH₂). Mass (*m/z*): 381.

4-(4-(1*H*-benzo[d]imidazol-1-yl)phenyl)-
6-(4-bromophenyl)pyrimidin-2-amine (**8f**)

% Yield: 45. MP (°C): 138–140. IR (KBr, cm⁻¹): 3086, 3410, 1521, 1234, 594. ¹H NMR (DMSO, 400 MHz) δ : 8.41(3H, t, Ar-H), 8.12(2H, d, imidazole), 7.81–7.73(3H, m, Ar-H), 7.67–7.63(4H, m, Ar-H), 7.38–7.31(2H, m, Ar-H), 6.38(2H, s, -NH₂). Mass (*m/z*): 442.

4-(4-(1*H*-benzo[d]imidazol-1-yl)phenyl)-6-
phenylpyrimidin-2-amine (**8g**)

% Yield: 45. MP (°C): 185–187. IR (KBr, cm⁻¹): 3086, 3323, 1544, 1224. ¹H NMR (DMSO, 400 MHz) δ : 8.30(2H, d, Ar-H), 8.19(1H, s, imidazole), 8.10–8.07(2H, m, Ar-H), 7.92–7.8(1H, m, Ar-H), 7.67(2H, d, imidazole), 7.53–7.39(4H, m, Ar-H), 7.39–7.35(2H, m, Ar-H), 7.26(1H, s, pyrimidine), 5.28(2H, s, -NH₂). Mass (*m/z*): 363.

4-(4-(1*H*-benzo[d]imidazol-1-yl)phenyl)-6-(4-
chlorophenyl)pyrimidin-2-amine (**8h**)

% Yield: 46. MP (°C): 161–164. IR (KBr, cm⁻¹): 3101, 3433, 1514, 1010, 742. ¹H NMR (DMSO, 400 MHz) δ : 8.40(3H, t, Ar-H), 8.18(2H, d, Ar-H), 7.93(1H, s, imidazole), 7.79(2H, d, imidazole), 7.65 (2H, t, Ar-H), 7.50(2H, d, Ar-H), 7.36–7.33(2H, m, Ar-H), 6.33(2H, s, -NH₂). Mass (*m/z*): 397.

4-(4-(1*H*-benzo[d]imidazol-1-yl)phenyl)-
6-(4-methoxyphenyl)pyrimidin-2-amine (**8i**)

% Yield: 48. MP (°C): 186–189. IR (KBr, cm⁻¹): 3070, 3477, 1512, 1031, 1232. ¹H NMR (DMSO, 400 MHz) δ : 8.80(3H, t, Ar-H), 8.14(2H, d, Ar-H), 7.79(1H, d), 7.7(2H, d, imidazole), 7.76(1H, d, Ar-H), 7.58 (1H, s, pyrimidine), 7.38–7.30(2H, m, Ar-H), 7.02(2H, d, Ar-H), 6.29(2H, s, -NH₂), 3.86(3H, s, -OCH₃). Mass (*m/z*): 393.

4-(4-(1*H*-benzo[d]imidazol-1-yl)phenyl)-6-(2,4-
dichlorophenyl)pyrimidin-2-amine (**8j**)

% Yield: 50. MP (°C): 128–130. IR (KBr, cm⁻¹): 3070, 3485, 1521, 1105, 736. ¹H NMR (DMSO, 400 MHz) δ : 8.49(1H, s, imidazole), 8.23(2H, d, imidazole), 7.78(3H, t, Ar-H), 7.76(2H, t, Ar-H), 7.59 (1H, s, pyrimidine), 7.47(1H, d, Ar-H), 7.37–7.29(3H, m, Ar-H), 6.73(2H, s, -NH₂). Mass (*m/z*): 431.

Biological activity

The splenic culture *L. donovani* was made in Medium-199 (L-glutamine with Hepes buffer without NaHCO₃) supplemented with 10% fetal bovine serum (pH 7.2). The logarithm phases of promastigotes (2×10^6 cells/ml) were incubated with or without the isolates along with Medium-199 at 22 °C. The samples were dissolved in 0.2% DMSO and then added to the culture in doses of 10 µg/ml. After 2 h of treatment, all tubes were centrifuged at $8,000 \times g$ for 10 min, the supernatant was decanted and the pellets were washed with 20 mM phosphate buffer saline (PBS). Each pellet was dissolved in 100 µl (2 mg/ml) of MTT in phosphate buffer saline.

All the tubes were incubated at 22 °C for 4 h and then centrifuged at $8,000 \times g$ for 10 min. All the pellets were dissolved in 500 µl DMSO and assessed by UV spectrophotometry (UV 2060 plus—Analytical India) at 570 nm. Percent of lysis of promastigotes by the compounds was calculated using the standard formula of Tim Mosmann. Chloroform (0.1% CHCl₃) treatment served as control.

$$\text{Lysis (\%)} = 100 - (T - PC)/(C - PC) \times 100 \quad (1)$$

T is the test isolate, *PC* is the positive control—meglumine antimolate, *C* is the control.

Acknowledgment The authors are grateful to Government of India (Ministry of Human Resource Development) for financial support.

References

- Agarwal KC, Sharma V, Shakya N, Gupta S (2009) Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents. *Bioorg Med Chem Lett* 19:5474–5477
- Bhandari K, Srinivas N, Marrapu VK, Verma A, Srivastava S, Gupta S (2010) Synthesis of substituted aryloxy alkyl and aryloxy aryl alkyl imidazoles as antileishmanial agents. *Bioorg Med Chem Lett* 20:291–293
- Bouhlef A, Curti C, Dumetre A, Laget M, Crozet MD, Azas N, Vanelle P (2010) Synthesis and evaluation of original amidoximes as antileishmanial agents. *Bioorg Med Chem* 18:7310–7320
- Chandra N, Ramesh A, Goyal N, Suryawanshi SN, Gupta S (2005) Antileishmanial agents part-IV: synthesis and antileishmanial activity of novel terpenyl pyrimidines. *Eur J Med Chem* 40:552–556
- Hussain T, Siddiqui HL, Rehman MZ, Yasinza MM, Parvez M (2009) Anti-oxidant, anti-fungal and anti-leishmanial activities of novel 3-[4-(1H-imidazol-1-yl) phenyl]prop-2-en-1-ones. *Eur J Med Chem* 44:4654–4660
- Micky JJA, Saleh NM, Mohamed SM, Mohamed SA, Salem MM (2006) Reaction and antimicrobial activity of 1-arylethylene benzofuran ketone derivatives. *Indian J Chem* 45B:1579–1583
- Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, Croft SL, Sundar S, Castanys S, Gamarro F (2006) Mechanisms of experimental resistance of *Leishmania* to miltefosine: implications for clinical use. *Drug Resist Update* 9:26–39
- Rashinkar GS, Pore SB, Mote KB, Salunkhe RS (2009) An efficient synthesis of novel 2-amino-4-aryl-6-ferrocenyl pyrimidine. *Indian J Chem* 48B:606–610
- Srinivas N, Palne S, Nishi, Gupta S, Bhandari K (2009) Aryloxy cyclohexyl imidazoles: a novel class of antileishmanial agents. *Bioorg Med Chem Lett* 19:324–327
- Sunduru N, Agarwal A, Katiyar SB, Nishi, Goyal N, Gupta S, Chauhana MS (2006) Synthesis of 2,4,6-trisubstituted pyrimidine and triazineheterocycles as antileishmanial agents. *Bioorg Med Chem* 14:7706–7715
- Sunduru N, Nishi PalneS, Chauhan PMS, Gupta S (2009) Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines. *Eur J Med Chem* 44:2473–2481
- Trivedi AR, Dodiya DK, Ravat NR, Shah VH (2008) Synthesis and biological evaluation of some new pyrimidines via a novel chalcone series. *Arkivoc* 11:131–141